AMARANTUS BIOSCIEN COM USD0.001 (AMBS)

0.03
0.00 12.21
OTC
Prev Close 0.03
Open 0.04
Day Low/High 0.03 / 0.04
52 Wk Low/High 0.01 / 0.09
Volume 948.90K
Exchange OTC
Shares Outstanding 78.79B
Market Cap 2.76M
Div & Yield N.A. (N.A)

Latest News

Amarantus Appoints Curtis Scribner, MD MBA As Sr. Vice President Of Regulatory Affairs

Amarantus Appoints Curtis Scribner, MD MBA As Sr. Vice President Of Regulatory Affairs

Dr. Scribner to Focus on Accelerated Regulatory Pathway for ESS

Amarantus To Present At The 2015 Aegis Growth Conference

Amarantus To Present At The 2015 Aegis Growth Conference

- Presentation and Live Webcast on October 9, 2015 at 11:25 a.m. PDT -

Amarantus Closes $5.5 Million Capital Infusion Through The Issuance Of A Combination Of Preferred Stock And Secured Debt Convertible

Amarantus Closes $5.5 Million Capital Infusion Through The Issuance Of A Combination Of Preferred Stock And Secured Debt Convertible

Company Simultaneously Repurchases All Outstanding Series G Convertible Preferred Stock

Amarantus Diagnostics Establishes Strategic Advisory Committee

Amarantus Diagnostics Establishes Strategic Advisory Committee

Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies

Amarantus Completes Acquisition Of ESS From Lonza For The Treatment Of Severe Burns

Amarantus Completes Acquisition Of ESS From Lonza For The Treatment Of Severe Burns

Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS)